English, Article edition: Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden: Analysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial Mattias Ekman; Niklas Zethraeus; Bengt Jonsson

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119840
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden: Analysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial
Author
  • Mattias Ekman
  • Niklas Zethraeus
  • Bengt Jonsson
Physical Description
  • article
Notes
  • Objective: To investigate the cost effectiveness of adding the beta-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF). Design and setting: A cost-effectiveness study was based on the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised clinical trial investigating the efficacy of adding bisoprolol to standard therapy of CHF. The cost-effectiveness analysis was carried out from a societal perspective. Methods: Health effects were measured in terms of years of life gained. On the cost side, treatment costs for pharmaceuticals and hospitalisations were included. Data on healthcare resource consumption from CIBIS-II were used and were combined with average Swedish retail prices for medicines, and average costs for hospitalisations based on hospital admissions, in the base case. The costs of added years of life, i.e. consumption net of production during life-years gained were also included. Results: If costs of added years of life were not included, then bisoprolol therapy increased life expectancy at an incremental cost of Swedish kronor (SEK) 13 094 (1999 values) per year of life gained. If costs of added years of life were included, then the incremental cost-effectiveness ratio of bisoprolol therapy was SEK168 858 per year of life gained. Conclusions: For patients with CHF with the characteristics of those in CIBIS-II, the cost effectiveness of bisoprolol therapy compares favourably with that of other cardiovascular therapies.
  • Beta 1 adrenoceptor antagonists, Bisoprolol, Congestive heart failure, Cost analysis, Pharmacoeconomics
  • RePEc:wkh:phecon:v:19:y:2001:i:9:p:901-916
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment